Posts Feed
Comments Feed

Archive for the 'Clinical Trials' Category

Prevention Of Organ Rejection In Stable Kidney Transplant Patients - LCP-Tacro? Moves Into Clinical Phase 3

Jan 3rd 2009Drug InformationClinical Trials

LifeCycle Pharma A/S (OMX:LCP) today announced the enrollment of the first patient in it’s Phase 3 clinical trial program for use of LCP-Tacro? in the prevention of organ rejection in stable kidney transplant patients. The clinical trial protocol has been reviewed by FDA, and LCP expects to enroll approximately 300 stable kidney transplant patients in the program. The study will be conducted at approximately 50 sites in U.S.

More: continued here

No Comments »

StemCells, Inc. Receives FDA Approval To Initiate Clinical Trial Of HuCNS-SCŪ Cells In A Myelin Disease

Jan 3rd 2009Drug InformationClinical Trials

StemCells, Inc. (NASDAQ:STEM) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to initiate a clinical trial of the Company’s proprietary HuCNS-SC product candidate (purified human neural stem cells) to treat Pelizaeus-Merzbacher Disease (PMD), a fatal brain disorder that mainly affects young children. This Phase I trial is designed to evaluate the safety and preliminary efficacy of HuCNS-SC cells as a treatment for PMD.

More: continued here

No Comments »

Resolvyx Announces Initiation Of Phase I/II Clinical Trial Of Novel Resolvin Therapeutic RX-10045 In Patients With Dry Eye

Jan 3rd 2009Drug InformationClinical Trials

Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced that it has initiated the first human clinical trial evaluating a resolvin therapeutic, RX-10045, in a Phase I/II clinical trial in patients with moderate-severe dry eye syndrome. RX-10045 is a synthetic analog of RvE1, a naturally occurring resolvin with potent anti-inflammatory and cell-sparing activities in laboratory testing.

More: continued here

No Comments »

« Prev - Next »

1